ArticleFrontiers in oncology2025
The prognostic significance of lung immune prognostic index in patients with osteosarcoma after chemotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma is the most common primary malignant bone tumor. However, research on predicting the prognosis of patients with osteosarcoma after chemotherapy (POC) remains limited. Notably, the Lung Immune Prognostic Index (LIPI) has emerged as a novel and effective prognostic factor in lung cancer. Therefore, this study aims to explore the prognostic significance of LIPI in POC for the first time, providing new insights and a foundation for evaluating the prognosis of these patients. Methods: This retrospective study analyzed patients with POC who were admitted to our center between January 2012 and January 2022. Hematological and clinical characteristics were collected and systematically evaluated. Kaplan-Meier survival analysis and Cox regression models were employed to assess the associations between various prognostic factors and overall survival (OS). Independent risk factors influencing OS were identified through both univariate and multivariate analyses. Based on these findings, a LIPI nomogram model was developed to predict OS in patients with POC. Results: This study included 150 patients who underwent chemotherapy, with 41 (27%), 80 (53%), and 29 (19.3%) classified into poor, moderate, and good prognostic categories, respectively, based on the LIPI classification (P < 0.0001). Time-dependent receiver operating characteristic (ROC) curve analysis demonstrated that LIPI exhibited superior prognostic predictive capability compared to other hematological and clinical parameters. Univariate and multivariate analyses identified LIPI as an independent prognostic factor. A nomogram was subsequently developed by integrating significant prognostic variables. Calibration curves confirmed the nomogram's accuracy in predicting three- and five-year overall survival (OS) post-chemotherapy. Furthermore, decision curve analysis indicated that the LIPI-based nomogram would provide substantial clinical benefits for chemotherapy patients. Conclusion: This study assessed the prognostic efficacy of LIPI in patients with POC and developed a LIPI-based nomogram to assist clinicians in predicting three- and five-year overall survival (OS). The proposed model has the potential to facilitate timely interventions and guide personalized management strategies, thereby improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.